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1. Introduction 
Malignant mesothelioma (MM) is a rare malignant disease originating from neoplastic 
mesothelial cells which compose the serous membranes of pleura, peritoneum, pericardium, 
or testis. Mesothelioma responds little to chemo and radiotherapy and is associated with a 
poor prognosis. In Western Europe, the incidence is increasing and is expected to peak in the 
year 2020 (Peto et al., 1999; Pelucchi et al., 2004) while in Japan and Australia, the peak is 
expected for 2025 and 2015 respectively. Thus in order to improve the clinical outcome in the 
pharmacological treatment of this refractory tumour, drugs directed against novel and/or 
characterized tumour-specific cellular targets are needed. Malignant pleural mesothelioma 
(MPM) originates from the pleural layers. Pleura is not just a limiting protective layer for lung, 
but a dynamic cellular structure regulating serial responses to injury, infection, and disease. 
Mesothelial cells are biologically active because they can sense and respond to signals within 
their microenvironment. The development of MM is associated in most patients with a history 
of asbestos exposure (Mossman et al., 1996). In addition, some investigations have implicated 
SV40 virus in the pathogenesis of a subset of mesotheliomas (Carbone et al., 2003). Exposure to 
asbestos typically occurs during mining and milling of the fibers or during industrial 
application of asbestos in textiles, insulation, shipbuilding, brake lining mechanics, and other 
areas. Non occupational exposure is usually related to asbestos fibers inadvertently released 
into the environment and transported by asbestos-contaminated clothing or other materials. 
After asbestos inhalation, fibers deposited in the lungs typically remain in close contact with 
lung epithelial cells. Since this fiber-cell interaction could potentially initiate or inhibit cellular 
functions, asbestos acts as a carcinogen by initiating the carcinogenic process. Carcinogens are 
known to modulate the transcription factors, anti-apoptotic proteins, proapoptotic proteins, 
protein kinases, cell cycle proteins, cell adhesion molecules, cyclooxygenase-2, and growth 
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factor signaling pathways. Research has demonstrated that asbestos exposure generates 
reactive oxygen species and activates macrophages and other cell types to produce these 
compounds as well as cytokines and growth factors (Kamp & Weitzman, 1999). Furthermore, 
the deposition of insoluble amphibole fibers results in a chronic inflammatory state and 
increased rates of MM in exposed individuals (Mossman & Churg, 1998). This article reviews 
recent studies regarding some MM molecular targets involved in inflammation for not only 
prevention but also for therapy of this deadly cancer. 
2. MM molecular targets involved in inflammation  
The existence of inflammation has been associated with up-regulation of the inducible 
cyclooxygenases-2 (COX-2), leading to an increase in its product prostaglandin-E2 (PGE-2) 
(Vane et al., 1994), and is associated with an increased risk of cancer (Ambs et al., 1999). 
Considerable evidence indicates that COX-2–derived PGE2 can activate epidermal growth 
factor receptor (EGFR) signaling and thereby stimulate cell proliferation. The mechanism(s) 
by which this occurs seem to be complex and context specific. Regardless of the precise 
mechanism for doing so, exposure to COX-2–derived PGE2 can initiate a positive feedback 
loop whereby activation of EGFR results in enhanced expression of COX-2 and increased 
synthesis of prostaglandins (Lippman et al., 2005). Although there is a crosstalk between 
EGFR and COX-2 in carcinogenesis it is important to stress that EGFR and its downstream 
effectors can be activated independently of COX-2/PGE2. For example, in MM, asbestos 
fibers activate the EGFR resulting in activation of extracellular signal regulated kinase 
downstream (Shukla et al., 2011). Similarly, COX-2/PGE2 and its downstream effectors can 
be regulated independently of EGFR signaling. For example, PGE2 is able to rapidly 
stimulate Erk phosphorylation in a subset of non–small cell lung cancer (NSCLC) cell lines 
via intracellular activation of kinase cascades independently of the proteolytic release of 
EGFR ligands via Src. (Gutkind, 1998; Krysan et al., 2005). These findings have provided the 
underpinnings for developing agents targeting EGFR or COX-2. A recent study with COX-2 
and EGFR inhibitors in MM has shown that the differences in the susceptibility to drugs 
could be due to the differences in the signalling pathways affected, in addition to the 
responses that may depend on cell type. In particular it was demonstrated in the Ist-Mes-2 
MM cell line a synergistic effect on the inhibition of cell growth between the active small 
molecule inhibitor of EGFR, gefitinib and rofecoxib, a drug that specifically targets COX-2. 
Interestingly, the other two cell lines sensitive to treatment with single drugs Ist-Mes-1 and 
MPP89, did not display this synergistic effect. Only in Ist-Mes-2, the cell line where p-AKT 
was not detectable, did the combination of rofecoxib and gefitinib result in a synergistic 
effect. This study suggests that identifying the mechanisms that underlie these differences in 
sensitivity of cell lines of MM single agents and their combinations, can help us to explore 
new proteins involved in drug resistance. (Stoppoloni et al., 2010). Lately a new therapeutic 
target, the Aromatase (CYP19A1), has been identified in MM. This new discovery has 
highlighted the possibility that there may be in MM as well as in breast cancer a relationship 
between inflammation, COX-2, EGFR and Aromatase (Fig.1)(Chumsri et al. 2011. These key 
molecules and pathways that connect chronic inflammation with inflammation associated 
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oncogenic transformation will be described. We emphasize how the increased 
understanding of the role of COX-2, EGFR and CYP19A1 in MM may provide novel 
preventive, diagnostic and therapeutic strategies for MM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Posible relationship among inflammation, COX-2, EGFR and Aromatase. 
Arachidonic acid (AA) metabolic pathway can be activated by inflammation (Stimulus). AA 
is released from membrane phospholipids by a phospholipase named phospholipase A2 
(PLA-2) enzyme and converted to bioactive PGE-2 by COX-2. PGE2 is an important regulator 
of CYP19A1 gene expression and stimulates CYP19A1 activity to increase localized estrogen 
17-beta-estradiol (E2). The E2 binds to the classical estrogen receptor (ER) to promote its 
dimerization and translocation to the nucleus where it modulates the expression of estrogen 
target genes (COX-2). The interaction of E2 with ER-alpha also activates signaling cascades 
that promote cell proliferation, such as the activation of of c-Src tyrosine kinase (Src). Src can 
also be activated by binding of PGE2 to its receptor (EP). Src activation induces the EGFR 
phosphorilation and stimulates the matrix metalloproteinase cascade which culminates in 
the liberation of epidermal growth factor (EGF). Free EGF ligand binds to EGFR family 
receptors that activates extracellular-signal-regulate- kinase (ERK). Cytosolic phospholipase 
A2 (cPLA) is a substrate for ERK and phosphorylation of cPLA (cPLAp) promotes its 
association with intracellular membranes such as those of the endoplasmic reticulum and 
mitochondria and releases lysophospholipids and AA from these membranes. COX-2 
catalyses the conversion of AA into PGE-2. 
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2.1. Cyclooxygenases  
COXs, also known as prostaglandin-endoperoxide synthases, are key regulatory enzymes in 
the biosynthesis of prostanoids, a class of hormones including prostaglandins, prostacyclins, 
and thromboxanes responsible for multiple inflammatory mitogenic, and angiogenic 
activities in various tissue and organ systems. Increasing interest on COXs is due to the 
many evidences showing the involvement of these enzymes not only in physiologic but 
even in pathophysiologic processes such as development and progression of cancer. Two 
COX isoforms have been identified as COX-1 and COX-2. COX-1 is expressed constitutively 
in several cell types of normal mammalian tissues, where it is involved in the maintenance 
of tissue homeostasis. In contrast, COX-2 is an inducible enzyme responsible for PGE2 
production at sites of inflammation (Harris, 2007). The mechanism through which COX-2 
exherts its tumorigenic action can be directly mediated by the enzyme or due to effects of its 
products. COX-2 is an oxygenase and its intermediates are highly reactive. It is possible that 
these compounds may cause free radical damage, for example, against DNA molecule 
(Cardillo et al., 2005) . There is considerable evidence that prostaglandins, participate both in 
normal growth responses and in aberrant growth, including carcinogenesis (Greenhough et 
al., 2009). PGE2 exerts its autocrine/paracrine effects on target cells by binding to four types 
of membrane-bound, G protein-coupled receptors termed as EP1, EP2, EP3, and EP4 (E-
series prostanoid receptors ) (Narumiya et al. 1999). These receptors are often coexpressed in 
the same cell type and use different, and in some cases, opposing intracellular signalling 
pathways (Breyer et al. 2001).Following ligand binding, the EP receptors activate different 
signal transduction pathways. EP1 raises intracellular Ca2_, whereas EP3 reduces or 
increases cyclic -adenosin monophosphate (cAMP) by activating inhibitory G (Gi) or 
stimulatory G (Gs) proteins depending on the particular splice variant expressed by the cell 
(Kotani, M  et al. 1995). The EP2 and EP4 receptors increase intracellular cAMP by activating 
adenylate cyclase via Gs proteins. However, differences in the strength of Gs coupling, 
activation of other signal transduction pathways, agonist-induced desensitization, and 
agonist-induced internalization result in a differential response of the target cell to a ligand-
induced activation of the EP2 or EP4 receptors (Akaogi et al. 2006).It was shown that PGE2 
stimulation of both EP2 and EP4 receptors involves transactivation of the epidermal growth 
factor receptor (EGFR) signaling pathway to promote tumorigenesis (Buchanan et al.; Pai et 
al 2003; Sale set al. 2005 ). PGE-2 promotes tumor growth with subsequent enhancement of 
cellular proliferation, promotion and angiogenesis, stimulation of invasion/mobility, 
suppression of immune responses and inhibitiuon of programmed cell death by inducing 
expression of the Bcl-2 protooncogene  (which can suppress apoptosis) (Cardillo et al.,2005) 
(Fig.2).  
 
Figure 2. PGE2 in carcinogenesis  
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For several types of cancer the real risk factor seems to be chronic inflammation (Prescott & 
Fitzpatrick, 2000) that maintains high level of COX-2 and increase events that promote 
tumor formation. A tragic example of this mechanism is MM. Although molecular 
mechanisms of asbestos tumorigenicity have not been elucidated, research has shown that 
deposition of insoluble amphibole fibers results in a chronic inflammatory state (Mossman 
& Churg, 1998) and that this state generates reactive oxygen and nitrogen species, as well as 
cytokines and growth factors, through the activation of macrophages and other cell types 
(Kamp & Weitzman, 1999).  
As expected, the prolonged inflammation causes the increase of COX-2 level, that is actually 
recognized as an important MM prognostic factor (Edwards et al., 2002; Mineo et al., 2010). 
A study clearly demonstrated that COX-2 expression is a strong prognostic factor in human 
mesothelioma, which contributes independently to the other clinical and histopathologic 
factors in determining a short survival (Edwards et al., 2002). Although the regulation of 
mRNA stability appears to be the most important regulatory step for COX-2 expression, 
several studies have reported that other mechanisms, such as transcriptional control or 
hypermethylation (Dixon et al., 2000), also are involved in the regulation of COX-2 
expression. In cancer cells, it was demonstrated previously that altered post-transcriptional 
regulation of COX-2 is mediated by increased cytoplasmic mRNA binding of the mRNA 
stability factor HuR (Dixon et al., 2001). In MM, the cytoplasmic expression of HuR was 
correlated significantly with high COX-2 expression and with poor survival (Stoppoloni et 
al.,2008). Finally, COX-2 has been proposed to exert its influence on mesangial cell 
proliferation in vitro by a novel mechanism involving the tumor suppressor p53 and the cell 
cycle inhibitors p21 and p27 (Zahner et al., 2002). Interestingly, several studies have 
investigated the potential prognostic value of p53, p21 and p27 in malignant mesotheliomas, 
thus reinforcing the evidence of a primary role of COX-2 in the pathogenesis and 
progression of MM (Bongiovanni et al., 2001; Baldi et al., 2002). Due to the lack of a reliable 
treatment capable of achieving long-term control in mesothelioma patients, these enzymes 
are becoming more and more appealing as potential therapeutic targets (Veltman et al., 
2010; Stoppoloni et al., 2010; O'Kane et al., 2010) 
2.2. Epidermal growth factor receptor  
The epidermal growth factor receptor (EGFR) is the cell-surface receptor for members of the 
epidermal growth factor family (EGF-family) of extracellular protein ligands (Herbst, 2004). 
Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive 
monomeric form to an active homodimer. In addition, EGFR may pair with another member 
of the ErbB receptor family, such as ErbB2/Her2/neu, to create an activated heterodimer. 
EGFR dimerization stimulates its intrinsic intracellular protein-tyrosine kinase activity. As a 
result, autophosphorylation of several tyrosine residues in the C-terminal domain of EGFR 
occurs (P-EGFR). This autophosphorylation leads to the activation of downstream signalling 
cascades including the RAS/extracellular signal regulated kinase (ERK) pathway, the 
phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway and the Janus kinase/Signal 
transducer and activator of transcription (JAK/ STAT) pathway (Fig.3).  
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Figure 3. Activation of downstream signaling cascade by P-EGFR 
These pathways act in a coordinated manner to promote cell survival (Oda et al., 2005). Such 
proteins modulate phenotypes such as cell migration, adhesion, and proliferation. EGFR is 
reportedly over-expressed in a wide variety of malignancies. Various studies suggest that 
receptor tyrosine kinase activation participates in the oncogenic progression of non 
neoplastic mesothelial progenitor cells to malignant mesothelioma. Asbestos fiber interact 
with the external domain of the EGFR to cause dimerization, activation and increased EGFR 
mRNA and protein levels in rat and human SV-40 immortalized mesothelial cells (Shukla  et 
al., 2011). Up-regulated EGFR and resulting tyrosine phosphorylation leads to the Ras 
activation which phosphorylates directly and activates Raf (Rapidly Accelerated 
Fibrosarcoma). Raf is responsible for phosphorylation of the mitogen associated / 
extracellular regulated kinase-1 (MEK) which in turn phosphorylates extracellular regulated 
kinases (ERK) on specific residues of threonine and tyrosine (Ras-Raf-MEK-ERK mitogen 
activated protein kinase (MAPK) pathway). ERK activates a variety of substrates involved in 
cell cycle. The ERK family consists of at least seven isoforms, and little is known about their 
regulation and function. ERK1/2 phosphorylation by asbestos, is dependent on 
phosphorylation of the EGFR. Moreover, has been shown that ERK5, a redox-sensitive 
kinase known to mediate c-jun proto-oncogene expression is activated by asbestos. ERK1/2 
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and ERK5 are all important in asbestos-induced proliferation and this may be the result of 
increases in the mRNA levels of AP-1 family members. The ERK5 pathway may be 
contributing selectively to the regulation of c-jun, whereas ERK1/2 pathways may regulate c-
fos, fra-1 and c-jun. Has been linked ERK1/2-dependent fra-1 expression to mesothelial cell 
transformation by asbestos and the protracted expression of this gene may be a result of 
initial increases in c-fos and c-jun (Scapoli et al., 2004). The phosphoinositide 3-kinase 
(PI3K)/AKT pathway, plays a critical role for the cell cycle progression in human MM cells [ 
Altomare et al.,2005). AKT, and the downstream mTOR are involved in cell growth and 
survival, and they are often found to be activated in MM (Carbone et al., 2012). It was 
reported previously that STAT1 and STAT3 are deregulated MM (Kothmaier et al., 
2008).The JAK/STAT signalling pathway is the principal signalling mechanism for growth 
factors in mammals. JAK activation induces a variety of biological responses such as cell 
proliferation, diff erentiation and cell migration. In addition, MM cell lines are reported to 
express EGFR and transforming growth factor-α (TGF-α), suggesting an autocrine role for 
EGFR in MM (Cai et al., 2004; Jänne et al., 2002). EGFR immunopositivity has been indicated 
as a poor prognostic factor in many solid tumors in the past (Nicholson et al., 2001). The 
EGFR expression in MM has been previously reported, with controversial results, possibly 
due to the lack of standardized method for EGFR detection and quantification (Dazzi et al., 
Destro et al., 2006; 1990; Govindan et al., 2005; Ramael et al., 1991; Trupiano et al., 2004). 
Until now, the role of immunohistochemistry (IHC) EGFR positive staining in influencing 
prognosis of MM is not clear. Some authors did not find differences in survival when IHC 
EGFR positive or negative staining were compared (Destro et al., 2006; Okuda et al., 2008). 
This is because only few reports analyzed the effect of IHC EGFR positive status and cell 
subtype in MM patients. Recently EGFR overexpression is identified by IHC in 52% of 
epithelial MM and is demonstrated to be a factor negatively affecting prognosis (Rena et al., 
2011). In view of these studies, EGFR was targeted for MM therapy, but despite the high 
expression of EGFR not all cells are sensitive to EGFR inhibitors (Garland et al., 2007). Many 
efforts are now directed to understand the lack of sensitivity of MM to EGFR inhibitors. In one 
such study, EGFR mutations were found in 31% (9 of 29) of malignant mesothelioma cases. 
Seven of these mutations were novel, and one was the L858R mutation described in NSCLC 
(Foster et al., 2009). Activating EGFR mutations in MM associated with optimal resectability 
and prolonged survival. Clinically these mutations may ultimately have utility in patient 
selection for surgery, systemic therapy, and selection for EGFR-TKI (tyrosine kinase inhibitor). 
The clinical course of MM patients with EGFR mutant tumors appear to share same 'relative' 
improved clinical outcome like mutant EGFR-NSCLC (Foster et al., 2010 . Study shows the 
ineffectiveness of the EGFR inhibitors due to coactivation of multiple receptor tyrosine kinase 
(EGFR, ERBB3, MET, and AXL) in individual mesothelioma cell lines (Ou et al., 2011) Thus, a 
combination therapy, could be a winning strategy in the treatment of mesothelioma. 
2.3. Aromatase 
A novel marker of MM recently identified is the CYP19A1 (Stoppoloni et al., 2011). 
CYP19A1 is the cytochrome P450 enzyme complex that converts C19 androgens to C18 
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estrogens. The human CYP19A1 gene, located in the 21.2 region on the long arm of 
chromosome 15 (15q21.2), spans a region that consists of a 30 kb coding region and a 93 kb 
regulatory region. Its regulatory region contains at least 10 distinct promoters regulated in a 
tissue- or signalling pathway-specific manner. Each promoter is regulated by a distinct set of 
regulatory sequences in DNA and transcription factors that bind to these specific sequences. 
These partially tissue-specific promoters are used in the gonads, bone, brain, vascular tissue, 
adipose tissue, skin, foetal liver, and placenta for estrogen biosynthesis necessary for human 
physiology (Bulun et al., 2004). Estrogens contribute to differentiation and maturation in 
normal lung (Patrone et al., 2003) and also stimulate growth and progression of lung tumors 
(Stabile et al., 2002; Pietras et al., 2005). Two major pathways, generally termed genomic and 
non-genomic, are known to mediate estradiol effects on cells. (Fig.4) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Estrogen Receptor fuction: Genomic (Nuclear ER) and Non Genomic (Membrane ER) action 
Estradiol has traditionally been described to mediate its effects via intracellular receptors 
located in the cytoplasm or on the nuclear membrane and thus studies have investigated the 
effect of estradiol on transcription factors in the regulation of target genes . Estradiol also 
acts on the plasma membrane to initiate signaling pathways in the cytoplasm and regulate 
cellular functions, which is called the non-genomic pathway (Simoncini et al., 2004; 
Simoncini & Genazzani, 2003). PGE2 is thought to be an important regulator of CYP19A1 
gene expression (Zhao et al., 1996). PGE2 increased CYP19A1 activity level in MM cell lines 
(Stoppoloni et al., 2011). Over the last decade many studies have been carried out to identify 
potential CYP19A1 stimulatory factors: IL-6 was the most potent factor detected that could 
stimulate CYP19A1 activity (Reed et al., 1992). The MM cell lines were capable of releasing a 
constitutively high amount of IL-6 (>1,100 pg.mL supernatant-1 of confluent cultures) 
(Orengo et al., 1999). This could explain the presence of CYP19A1 in MM cells. Furthermore, 
estrogen receptor (ER) were also detected in MM cell lines by western blot. The classic 67 
kDa and a variant 46 kDa of ERα and 59 kDa of ERβ were expressed in MM cell lines. In 
support of these results there are recent literature data pointing to a role for estrogens in 
MM pathogenesis. Epidemiologic studies have identified female gender as a positive 
prognostic factor for MM (Pinton et al., 2009), although no experimental explanation of this 
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finding has been provided thus far. CYP19A1 was expressed in the majority of samples from 
patients with MM. Cytoplasmic expression of CYP19A1 significantly correlated with poor 
survival (Stoppoloni et al., 2011). The World Health Organization classifies MM into 
epithelial, sarcomatoid, and biphasic types, each of which can be subdivided further (Travis 
et al., 1999). This classification has implications for both diagnosis and prognosis. Prognosis 
is poor for all MMs, but sarcomatoid MMs have a particularly poor response rate to 
treatment (Neragi-Miandoab et al., 2008). A significant association between high expression 
of CYP19A1 and sarcomatoid MMs was found (Stoppoloni et al., 2011). These observations 
strongly suggest that CYP19A1 plays a role in tumour progression in MM. MM cell 
proliferation was significantly reduced by exemestane (aromatase inhibitor) treatment. 
Treatment of MM cells with exemestane led to significant reduction of tumor cell growth, 
perturbation of cell cycle, caspase activation, PARP cleavage, down-regulation of p-AKT 
and Bcl-xL. . Since Akt pathway as well as Bcl-xL are implicated in conferring resistance to 
conventional chemotherapy exemestane could open new treatment strategies to be 
associated with standard therapy for patients afflicted with MM (Stoppoloni et al., 2011). 
3. Conclusion  
COX-2, EGFR and CYP19A1 are investigational at the present time. The cross-talk between 
markers that have been described and their value as prognostic indicators will need to be 
validated in prospective studies in larger patient populations. Their role at the present time 
is to give us direction towards development of newer therapies in this very resistant tumor. 
The standard of care at the present time for malignant mesothelioma does not involve 
checking for these markers and making patient care decisions based on them. But we hope 
that in the near future this would become a reality with a better treatment approach and 
prognosis for these patients. Furthermore the possibility of using natural anti-inflammatory 
products in the chemoprevention of people at risk of MM can not exclude. 
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